Double-blind, Placebo-controlled Study on Men With Lower Urinary Tract Symptoms to Assess Changes in Pressure Flow Study and in Molecular Profile of Prostatic Tissue After 12 Weeks Treatment With Tadalafil.
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Tadalafil (Primary)
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Therapeutic Use
- 24 Sep 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 24 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated